Multiplex Antigen Near-Patient Tests in Respiratory Tract Infections

By Danélia Botes

November 7, 2023

Understanding Respiratory Tract Infections (RTIs)

RTIs are some of the most common illnesses, causing a significant number of outbreaks annually. Viruses such as SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) are often the culprits. These RTIs lead to a surge in hospital admissions during winter months, and their symptoms can be very similar, making it challenging to differentiate between them.

Multiplex Antigen Near-Patient Tests

Laboratories typically conduct the gold standard for these tests, reverse transcription polymerase chain reaction (RT-PCR). On the other hand, antigen near-patient tests (NPTs) offer quicker, more affordable, and easier testing. These tests can identify many viruses in multiplex tests or just one virus in singleplex tests, but they are less accurate overall. 

For the purpose of managing and identifying RTIs in primary and residential care settings, multiplex antigen NPTs may be helpful. Their viability and effectiveness are still unknown, though. Although the company states that these tests have acceptable diagnostic accuracy, there are questions regarding the sensitivity of these tests. This applies especially to RSV and influenza. This may reduce their usefulness in contexts involving primary or residential care.

The Current State of Affairs

There is limited guidance available on the use of multiplex antigen NPTs. Two international recommendations were identified, one from the Public Health Laboratory Network and Communicable Diseases Network Australia, which did not recommend the use of these tests. Another evaluation report by the Haute Autorité de Santé (HAS) in France found no clear medical benefit to using these tests in primary care settings. The World Health Organisation ACT-Accelerator Transition Plan has supported the development and acceleration of access to affordable COVID-19 rapid antigen diagnostic tests. This highlights potential interest in these and related technologies.

The Road Ahead

Given the uncertainties surrounding the effectiveness and feasibility of multiplex antigen NPTs in primary and residential care facilities, further studies are required. These studies should prospectively assess the diagnostic performance and clinical utility of multiplex antigen NPTs. The goal is to inform public policy on the use of these tests in these settings. Potentially helping to reduce inappropriate antibiotic use or emergency department visits for non-serious infections.

Reference url

Recent Posts

Biosimilars in Multiple Sclerosis
             

The Readiness of Biosimilars in Multiple Sclerosis Treatment

🌟 The role of biosimilars in Multiple Sclerosis treatment is expanding, offering more affordable and accessible options for patients.
Learn how these biologic medications are transforming MS care by reducing costs and increasing treatment options. 🧬💊
#SyenzaNews #Biosimilars #MultipleSclerosis #HealthcareInnovation #PatientCare #MedicalResearch

Geriatric-specific cancer rehabilitation
              

Enhancing Health Outcomes with Geriatric-Specific Cancer Rehabilitation

🌟 Exciting News! Learn how specialised geriatric cancer rehabilitation programmes are transforming health outcomes for older adults undergoing cancer treatment. Discover the effect of personalised care and comprehensive assessments in enhancing quality of life.

#SyenzaNews #GeriatricCancerRehabilitation #ElderlyCare #SeniorHealth #QualityofLife

Discover how geriatric-specific cancer rehabilitation can provide significant improvements in emotional health, social connectedness, and independence for seniors undergoing cancer treatment. Let’s work together to integrate these vital programs into oncology care pathways. 💪

Alzheimer's Treatments
                 

Alzheimer’s Treatments: Evaluating Emerging Therapies and NICE’s Stance on Lecanemab

🌟 #SyenzaNews: The landscape of Alzheimer’s treatment is evolving with new drugs on the horizon. While NICE recently found lecanemab’s benefits too small to justify its cost, promising treatments like donanemab, remternetug, and blarcamesine show potential. Learn more about these emerging therapies and their impact on Alzheimer’s care. 💊🧠
#AlzheimersResearch #HealthcareInnovation #PharmaNews #DementiaCare

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.